DOI QR코드

DOI QR Code

Correlations of obesity and elevated interleukin-6 levels with length of stay in COVID-19 patients in Korea: a retrospective study

국내 COVID-19 입원 환자의 비만, 상승된 인터루킨-6와 입원기간의 상관관계

  • Hyunjung Oh (College of Nursing, Chungnam National University.Department of Nursing, Chungnam National University Hospital) ;
  • Kyoungsan Seo (College of Nursing, Research Institute of Nursing Science, Chungnam National University)
  • 오현정 (충남대학교 간호대학.충남대학교병원) ;
  • 서경산 (충남대학교 간호대학.간호과학연구소)
  • Received : 2023.12.14
  • Accepted : 2024.04.20
  • Published : 2024.05.31

Abstract

Purpose: The purpose of this study was to investigate the associations of obesity and clinical characteristics including interleukin-6 (IL-6) with hospital length of stay (LOS) in coronavirus disease-2019 (COVID-19) patients in Korea. Methods: A retrospective descriptive study design was employed to analyze medical data from a government-designated hospital in a city of Korea. Clinical data were collected from 256 patients with COVID-19 in negative-pressure isolation wards in 2021. The following parameters were analyzed: body mass index (BMI), IL-6 levels, age, sex, comorbidities, healthy habitsat the time ofadmission, and LOS. The statistical package SPSS 26.0 was used for descriptive statistics, the independent t-test, the chi-square test, and partial correlation coefficients. Results: The age of COVID-19 patients was positively correlated with BMI (r = -.16, p = .012), IL-6 levels (r = .14, p = .022) and LOS (r = .26, p < .001). Obesity, non-drinking, hypertension, and older age were associated with longer LOS. Conclusion: These results suggest that age, obesity, and hypertension in COVID-19 patients are related to LOS. Studies investigating other factors that can affect long-term hospitalization in COVID-19 patients are suggested.

Keywords

Acknowledgement

This manuscript is based on a part of the first author's master's thesis from Chungnam National University.

References

  1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. The New England Journal of Medicine. 2020;382(8):727-733. https://doi.org/10.1056/NEJMoa2001017
  2. Korea Disease Control and Prevention Agency. COVID-19 for health care use. Symptoms and course [Internet]. Cheongju: Korea Disease Control and Prevention Agency; 2024 [cited 2024 Apr 17]. Available from: https://ncv.kdca.go.kr/pot/www/CVID19/CVID19_INFO/DFNTN.jsp
  3. Torres Acosta MA, Singer BD. Pathogenesis of COVID-19- induced ARDS: implications for an ageing population. European Respiratory Journal. 2020;56(3):2002049. https://doi.org/10.1183/13993003.02049-2020
  4. Centers for Disease Control and Prevention. People with certain medical conditions [Internet]. Atlanta: Centers for Disease Control and Prevention; 2024 [cited 2024 Apr 17]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
  5. Soeroto AY, Soetedjo NN, Purwiga A, Santoso P, Kulsum ID, Suryadinata H, et al. Effect of increased BMI and obesity on the outcome of COVID-19 adult patients: a systematic review and meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(6):1897-1904. https://doi.org/10.1016/j.dsx.2020.09.029
  6. Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit. JAMA Network Open. 2020;3(6): e2012270. https://doi.org/10.1001/jamanetworkopen.2020.12270
  7. Hernandez-Galdamez DR, Gonzalez-Block MA, Romo-Duenas DK, Lima-Morales R, Hernandez-Vicente IA, Lumbreras-Guzman M, et al. Increased risk of hospitalization and death in patients with COVID-19 and pre-existing noncommunicable diseases and modifiable risk factors in Mexico. Archives of Medical Research. 2020;51(7):683-689. https://doi.org/10.1016/j.arcmed.2020.07.003
  8. Ho FK, Celis-Morales CA, Gray SR, Katikireddi SV, Niedzwiedz CL, Hastie C, et al. Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK biobank prospective cohort study. British Medical Journal Open. 2020;10(11):e040402. https://doi.org/10.1136/bmjopen2020-040402
  9. Demeulemeester F, de Punder K. Obesity as a risk factor for severe COVID-19 and complications: a review. Cells. 2021; 10(4):933. https://doi.org/10.3390/cells10040933
  10. De Heredia FP, Gomez-Martinez S. Obesity, inflammation and the immune system. Proceedings of the Nutrition Society. 2012;71(2):332-338. https://doi.org/10.1017/S0029665112000092
  11. Tang CH, Lu DY, Yang RS, Tsai HY, Kao MC, Fu WM, et al. Leptin-induced IL-6 production is mediated by leptin receptor, insulin receptor substrate-1, phosphatidylinositol 3-kinase, Akt, NF-kappaB, and p300 pathway in microglia. The Journal of Immunology. 2007;179(2):1292-1302. https://doi.org/10.4049/jimmunol.179.2.1292
  12. Chiappetta S, Sharma AM. COVID-19 and the role of chronic inflammation in patients with obesity. International Journal of Obesity. 2020;44(8):1790-1792. http://doi.org/10.1038/s41366-020-0597-4
  13. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Seminars in Immunopathology. 2017;39(5):529-539. https://doi.org/10.1007/s00281-017-0629-x
  14. Fehr AR, Channappanavar R. Middle east respiratory syndrome: emergence of a pathogenic human coronavirus. Annual Review of Medicine. 2017;68:387-399. https://doi.org/10.1146/annurev-med-051215-031152
  15. Paquette SG, Banner D, Zhao Z, Fang Y, Huang SS, Leόn AJ, et al. Interleukin-6 is a potential biomarker for severe pandemic H1N1 influenza A infection. PLoS One. 2012;7(6):e38214. https://doi.org/10.1371/journal.pone.0038214
  16. Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS One. 2021;16(3):e0247461. https://doi.org/10.1371/journal.pone.0247461
  17. Morris AE, Stapleton RD. The association between body mass index and clinical outcomes in acute lung injury. Chest. 2007;131(2):342-348. https://doi.org/10.1378/chest.06-1709
  18. Trnacevic A, Mujkanovic A, Al-Salloum N, Sakusic A, Trnacevic E, Jusufovic E, et al. COVID-19 in northeast bosnia and herzegovina and patient's length of hospitalization. BMC Infectious Diseases. 2021;21(1):367. https://doi.org/10.1186/s12879-021-06034-6
  19. Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in new york: retrospective case series. British Medical Journal. 2020;369:m1996. https://doi.org/10.1136/bmj.m1996
  20. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the seattle region - case series. The New England Journal of Medicine. 2020;382(21):2012-2022. https://doi.org/10.1056/NEJMoa2004500
  21. Korean Society for the Study of Obesity. Diagnosis and evaluation of obesity [Internet]. Seoul: Korean Society for the Study of Obesity; 2024 [cited 2022 May 2]. Available from: http://general.kosso.or.kr/html/?pmode= obesityDiagnosis
  22. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nature Reviews Immunology. 2011;11(2):85-97. https://doi.org/10.1038/nri2921
  23. Korea Disease Control and Prevention Agency. Protocol for investigating suspected COVID-19 infection (local government). 9-5 version [Internet]. Cheongju: Ministry of Health and Welfare; 2024 [cited 2022 May 2]. Available from: http://www.cdc.go.kr/board/board.es?mid = a20507020000&-bid= 0019
  24. Zeng J, Liu X, Wang S, Yang S, Jia W, Han K, et al. The association between BMI and metabolically unhealthy status with COVID-19 mortality: based on 3019 inpatients from Wuhan, China. Nutrition, Metabolism & Cardiovascular Diseases. 2021;31(11):3219-3226. https://doi.org/10.1016/j.numecd.2021.07.030
  25. Hamer M, Kivimaki M. Lifestyle risk factors, inflammatory mechanisms, and COVID-19 hospitalization: a community-based cohort study of 387,109 adults in UK. Brain, Behavior, and Immunity. 2020;87:184-187. https://doi.org/10.1016/j.bbi.2020.05.059
  26. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-513. https://doi.org/10.1016/S0140-6736(20)30211-7
  27. Potere N, Batticciotto A, Vecchie A, Porreca E, Cappelli A, Abbate A, et al. The role of IL-6 and IL-6 blockade in COVID-19. Expert Review of Clinical Immunology. 2021;17(6):601-618. https://doi.org/10.1080/1744666X.2021.1919086
  28. Bello S, Lasierra AB, Lopez-Vergara L, de Diego C, Torralba L, de Gopegui PR, et al. IL-6 and cfDNA monitoring throughout COVID-19 hospitalization are accurate markers of its outcomes. Respiratory Research. 2023;24(1):125. https://doi.org/10.1186/s12931-023-02426-1
  29. Gil S, Jacob Filho W, Shinjo SK, Ferriolli E, Busse AL, Avelino-Silva TJ, et al. Muscle strength and muscle mass as predictors of hospital length of stay in patients with moderate to severe COVID-19: a prospective observational study. Journal of Cachexia, Sarcopenia and Muscle. 2021;12(6):1871-1878. https://doi.org/10.1002/jcsm.12789
  30. Rees EM, Nightingale ES, Jafari Y, Waterlow NR, Clifford S, Pearson CAB, et al. COVID-19 length of hospital stay: a systematic review and data synthesis. BMC Medicine. 2020;18(1):270. https://doi.org/10.1186/s12916-020-01726-3
  31. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity. 2020;28(7):1195-1199. https://doi.org/10.1002/oby.22831
  32. Jaisinghani P, Kumar R. Obesity and viral infections. Gastroenterology Clinics of North America. 2023;52(2):393-402. https://doi.org/10.1016/j.gtc.2023.03.012
  33. Wehbe Z, Hammoud SH. Molecular and biological mechanisms underlying gender differences in COVID-19 severity and mortality. Frontiers in Immunology. 2021;12:659339. https://doi.org/10.3389/fimmu.2021.659339
  34. Le Guen CL, King NA. COVID-19 patients with obesity at risk for worse outcomes despite younger age and fewer inflammatory derangements. Surgery for Obesity and Related Diseases. 2021;17(10):1722-1730. https://doi.org/10.1016/j.soard.2021.06.006
  35. Hu B, Guo H. Characteristics of SARS-CoV-2 and COVID-19. Nature Reviews Microbiology. 2021;19(3):141-154. https://doi.org/10.1038/s41579-020-00459-7
  36. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, Villamizar-Pena R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Medicine and Infectious Disease. 2020;34:101623. https://doi.org/10.1016/j.tmaid.2020.101623
  37. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International Journal of Infectious Diseases. 2020;94:91-95. https://doi.org/10.1016/j.ijid.2020.03.017
  38. Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HHX, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. The Lancet Global Health. 2020;8(8):e1003-e1017. https://doi.org/10.1016/S2214-109X(20)30264-3